SCHEMBL22874995

SCHEMBL22874995

CC(C)C1CCN(C(=O)c2ccon2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA4 P43681 2/20 0.51
TLR9 Q9NR96 2/20 0.46
TLR8 Q9NR97 2/20 0.46
TLR7 Q9NYK1 2/20 0.46
GRM2 Q14416 1/20 0.46
CASP3 P42574 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
DGAT1 O75907 1/20 0.41
CNR2 P34972 1/20 0.40
SCD5 Q86SK9 2/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
THRB P10828 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20827312 0.79 CHRNA4 (0.54) CHRNA4TLR9TLR8TLR7GRM2
SCHEMBL20827310 0.79 NPC1 (0.62) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL30740773 0.78 CHRNA4 (0.58) CHRNA4NPC1RAB9ACNR2ALDH1A1
SCHEMBL2603239 0.77 KMT2A (0.56) CHRNA4NPC1RAB9AALDH1A1LMNA
SCHEMBL22874812 0.75 PIK3CD (0.51) KMT2ASMN1; SMN2
SCHEMBL22874996 0.75 NPSR1 (0.58) CHRNA4SCD5ALDH1A1MEN1KMT2A
SCHEMBL25270421 0.74 CHRNA4 (0.61) CHRNA4GRM2KMT2AHPGDCHRM2
SCHEMBL27490428 0.74 CHRNA4 (0.54) CHRNA4TLR9TLR8TLR7GRM2
SCHEMBL17540512 0.73 KMT2A (0.47) RAB9ACNR2MEN1KMT2A
SCHEMBL17540493 0.73 KDM5A (0.47) CNR2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 CHRNA4 3552/4885TLR9 4601/4885TLR8 4099/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 CHRNA4 3103/4885TLR9 4214/4885TLR8 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.